Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Bruno Brochet, Robert T Naismith, Anthony Traboulsee, Jerry S Wolinsky, Shibeshih Belachew, Harold Koendgen, Victoria Levesque, Marianna Manfrini, Fabian Model, Stanislas Hubeaux, Lahar Mehta & Xavier Montalban
Objective To assess over 3 years of follow-up, the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA studies in relapsing multiple sclerosis. Methods After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN) β-1a (44 μg 3 times weekly) to OCR when entering the OLE...
2 citations reported since publication in 2019.
329 views reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
102 downloads reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?